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Background—Many HIV-infected individuals present with advanced HIV disease. These 
patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for 
death in these patients are unclear.
Methods—We used data from a multi-site randomized trial comparing empiric versus preventive 
TB therapy in HIV-infected adults initiating ART with CD4 counts <50 cells/mm3 to evaluate risk 
factors for death within 48 weeks after ART initiation. Cox proportional hazards models were fit 
to evaluate characteristics present at baseline and at 4 weeks after ART initiation, including the 
week 4 CD4 cell response and new opportunistic infections (OIs).
Findings—Of 850 enrolled, the median pre-ART CD4 count was 18 cells/mm3 and 67 (7.9%) 
died. Baseline risk factors for death included lymphadenopathy, lower CD4 count, lower serum 
albumin, high white blood cell (WBC) count, elevated neutrophil percent, and lower hemoglobin. 
Among 746 participants with data at week 4, the median changes in CD4 count and viral load for 
those who died (n=43) vs. survived were 26 vs. 56 cells/mm3 and −2.7 vs. −2.7 log10 copies/mL, 
respectively. Each 20 cell/mm3 lower change in week 4 CD4 count was associated with a 20% 
increased risk of post week-4 mortality (adj. HR 1.20, 1.01–1.42, p=.038).
Interpretation—Evidence of active infection and sub-optimal immunologic response during the 
first month of ART are associated with death in the first year after ART initiation in those with 
advanced HIV disease taking TB preventative therapy. Strategies to reduce early mortality in this 
population warrant further investigation.
Introduction
Provision of antiretroviral therapy (ART) to HIV-infected individuals has saved millions of 
lives in resource-limited settings (1). However, CD4+ T-cell counts remain low among 
individuals presenting for care in many areas (2), and up to 17% of adults die in the first year 
after ART initiation (3). Risk factors for death in the initial year after starting ART (i.e., 
early mortality) include a low CD4 count, low body mass index (BMI), and anemia, with a 
CD4 count <50 cells/mm3 conferring particularly high risk (3).
World Health Organization (WHO) guidelines urge providers to screen HIV-infected patients 
for TB-associated symptoms and to start asymptomatic individuals on ART and isoniazid 
preventive therapy (IPT), which reduces TB-associated morbidity in HIV-infected 
individuals (4). To date, studies evaluating risk factors for early mortality have generally 
evaluated patients at all stages of HIV disease who receive care in settings where WHO 
recommendations on TB screening and IPT use are not implemented (3). These studies may 
not generalize to settings where TB screening and IPT are systematically performed, which 
is an increasingly important knowledge gap as efforts to improve implementation of these 
guidelines increases.
Studies evaluating risk factors for early mortality in large, diverse populations with advanced 
HIV are needed. Identifying factors associated with early mortality may enable formulation 
of therapeutic or diagnostic interventions. It is also important to understand how patients 
who die respond or fail to respond to ART. Because most who suffer early mortality die 
before responses to ART are assessed, responses and events early on ART in these 
individuals remain largely unknown. Early ART adherence has been shown to be high in 
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those suffering early adverse treatment outcomes, and one study evaluating patients 
initiating ART with advanced HIV and pulmonary TB found that sub-optimal CD4 recovery 
by week 4 was strongly associated with an increased risk of early mortality (5, 6). 
Opportunistic illnesses that emerge very early after ART initiation also confer an increased 
risk of early mortality, although most studies have focused on TB, which may be less 
common as implementation of TB screening and IPT improves (7, 8).
We used data from a large, multi-site international randomized trial of empiric TB therapy in 
HIV-infected adults initiating ART with CD4 counts <50 cells/mm3 to examine pre-ART 
risk factors for early mortality and to evaluate the associations between early (week 4) ART 
responses and emergent OIs and the risk of death between 4 and 48 weeks after ART 
initiation.
Methods
The study was approved by local ethics committees at the study sites.
Study design
We conducted a secondary analysis of a clinical trial to evaluate the association between 
baseline (pre-ART) characteristics and early mortality after ART initiation. Early mortality 
was defined as death within 48 weeks after ART initiation (henceforth referred to as early 
mortality). Baseline risk factors included demographics and pre-ART clinical characteristics 
including symptoms and WHO stage 3 and 4 OIs. In addition, we evaluated the association 
between early ART response, defined as the change in viral load and CD4 count from 
baseline (pre-ART) to week 4 after ART initiation, and death occurring between 4 and 48 
weeks after ART initiation (i.e., post-week 4 mortality). WHO stage 3 and 4 OIs newly 
diagnosed by week 4 were also included as risk factors in this analysis.
Study setting
AIDS Clinical Trials Group Study 5274 (A5274) is an international clinical trial that 
randomized ART-naïve, HIV-infected adults age 13 years or older with CD4 counts <50 
cells/mm3 1:1 in an open label design to a strategy of ART + four drug empiric TB therapy 
(Empiric arm) or ART+ IPT (IPT arm). As reported elsewhere, empiric TB therapy did not 
improve 24- or 48-week survival (9). The study took place at 18 sites in 10 countries, with 
78% of participants living in sub-Saharan Africa (9). All sites reported a TB incidence 
>100/100,000 person years and had ART programs with documented high early mortality 
rates (>10–20 per 100 person years) among outpatients. Sites generally followed guidelines 
for ART initiation within their country programs.
Study subjects
Potential trial participants were referred to study clinics from local ART clinics. At the study 
clinics, potential participants were screened for TB using a standard TB symptoms screen 
(9). Any positive screen required further workup as per local standard of care. All sites had 
capacity to perform AFB smear, chest radiograph, ultrasound, mycobacterial culture, and the 
Xpert MTB/RIF® assay. Use of specific tests was left up to site providers until June 2013, 
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when the Data Safety Monitoring Board requested that sputum Xpert MTB/RIF be 
performed prior to enrollment. Persons suspected of having TB, or for whom screening 
procedures identified confirmed or probable TB, were excluded. Participants without 
symptoms on screening or who had no microbiologic or clinical diagnosis of TB despite 
symptoms were eligible. Additional inclusion criteria included having liver function tests 
≤2.5× the upper limit of normal, creatinine clearance ≥30mL/min, and Karnofsky 
Performance Score ≥30. Exclusion criteria included use of single dose nevirapine in the 
preceding 2 years, receipt of TB treatment or IPT within 96 and 48 weeks prior to study 
entry, respectively, and a history of or household exposure to multidrug resistant (MDR)-TB 
(see appendix for full eligibility criteria).
Study treatments and data collection
All participants received efavirenz-containing ART with either study-provided tenofovir/
emtricitibine (Truvada®) or locally available nucleoside reverse transcriptase inhibitors. 
Participants in the Empiric arm received fixed-dose combination rifampin/isoniazid/
ethambutol/ pyrazinamide for 8 weeks, followed by fixed-dose combination rifampin/
isoniazid for 16 weeks, beginning within 7 days after ART initiation. Participants in the IPT 
arm received 300mg of isoniazid daily for 24 weeks, beginning within 7 days of ART. All 
participants received pyridoxine. Participants attended study visits at screening, enrollment, 
and weeks 1, 2, 4, 8, 12, 16, 20, 24, 36 and 48. Blood was collected for CD4 and HIV-1 
RNA at entry, week 4 and week 24. Those diagnosed with TB received TB drug resistance 
testing and standard TB treatment. Causes of death and WHO stage 3 and 4 diagnoses were 
externally adjudicated by an independent physician panel.
Statistical analysis
We considered two main analyses: time to death within 48 weeks after ART initiation (for 
analyses of baseline risk factors for early mortality), and time to death between weeks 4 and 
48 after ART initiation (for analyses of week-4 CD4 response, virologic response, and newly 
diagnosed OIs on ART and mortality). All deaths after week 4 were included in both 
analyses and the baseline risk factor analysis also included 9 deaths occurring between 
baseline and week 4. Participants who withdrew consent (n=8) or had an unknown vital 
status (n=2) were censored at the time of their last visit. Plots of survival curves were 
produced using the Kaplan-Meier method, with variables either dichotomized around the 
median value or at clinically meaningful cut-points. Risk related to baseline CD4 count was 
expressed in 10 cells/mm3 increments due to limited variability of CD4 counts in this highly 
advanced HIV population. Cox proportional hazards models and 95% confidence intervals 
(CIs) were used to estimate hazard ratios. Proportional hazards assumptions were assessed 
using plots of the observed score process for each covariate against simulated score 
processes under proportional hazards (10, 11). For the baseline analysis, adjusted hazard 
ratios are based on multivariable models that include the covariate of interest, and the pre-
specified covariates of age, sex, BMI, hemoglobin, CD4 count, and log 10 HIV-1 RNA. 
Since there were relatively few events (66) in the analysis, to avoid overfitting we used this 
approach rather than including all covariates of interest in a single model. For the post-
week-4 mortality analysis, a single model was fit with the covariates above and 4-week CD4 
change, 4-week viral load change, viral suppression (HIV-1 RNA < 400 copies/mL), and any 
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new opportunistic infections from baseline to week 4 (yes/no). This analysis was pre-
specified to test the association of mortality and 4-week CD4 change, adjusted for viral load 
and other key covariates. Trial study arm was not associated with survival (9) and was not 
included as a covariate.
Because there were few missing data at baseline, all eligible participants with hemoglobin, 
CD4 count, and viral load data were included in the analysis of baseline risk factors using 
complete case analysis (n=837). For the post-week-4 mortality analysis, participants who 
were alive but missing CD4 counts or viral load at week 4 or baseline hemoglobin, CD4 
count, or viral load were initially excluded (n=94). However, a multiple imputation (MI) 
analysis was performed to incorporate participants initially excluded for missing these data. 
Fully conditional specification with predictive mean matching imputation was performed as 
it is more robust to departures from multivariate normality (12) (13). The imputation model 
included all variables in the post-week-4 analysis model, the log of follow up time from 
week 4 to 48, survival status, and albumin, absolute neutrophil count, neutrophil percent, 
and white blood cell count. A total of 100 imputations were performed; results were 
combined using Rubin’s method (14). The validity of the multiple imputation analysis is 
based on the missing at random assumption; that the missing data depends on the observed 
data included in the model.
Those missing week-4 data because they had died or were lost to follow-up prior to week 4 
were not included in the post-week-4 analyses. We noted a very high mortality rate in 
participants who were alive at week 4 but missed their week-4 visit. We evaluated the 
possible effects of missing data at week 4 in these participants by 1) repeating the analysis 
with multiple imputation after excluding these individuals and 2) performing sensitivity 
analysis varying assumptions about these participants’ 4-week CD4 and viral load responses. 
Ten imputations were performed per sensitivity analysis. Change in CD4 count at week 4 
was expressed in increments of 20 cells/mm3 due to relatively high variability of this 
parameter. Analyses were performed with SAS Version 9.4 using procedures PHREG for the 
mortality analyses, LIFETEST and SGPLOT for Kaplan-Meier plots, and MI and 
MIANALYZE for the multiple imputation analysis. This study is registered in 
ClincalTrial.gov, trial number NCT01380080.
Study oversight
The trial was funded by the National Institutes of Allergy and Infectious Diseases (NIAID) 
through the AIDS Clinical Trials Group and was overseen by an NIAID-appointed Data 
Safety Monitoring Board.
Results
From October 31, 2011 until June 9, 2014, a total of 851 were randomized in A5274 
(Supplemental Figure 1)(9). Suspected or confirmed active illness including TB was a 
common reason for exclusion (Supplemental Figure 1). One participant was found to be 
ineligible after enrollment and was discontinued at day 10 for having a screening CD4 count 
≥ 50 cells/mm3. 443 enrolled participants had a chest x-ray done during screening.
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Thirteen participants, including 1 death, were missing CD4 count (n=3), viral load (n=6), or 
hemoglobin (n=4) values and were excluded from baseline analyses, leaving 837 
participants for further evaluation (Supplemental Figure 1). During 48 weeks of follow-up, 
66 of 837 (7.9%) participants died. Participant characteristics for the 66 deaths and 771 
survivors included in the baseline analysis are shown in Table 1. Specific OIs present at 
baseline are given in Supplemental Table 1. Table 2 summarizes all 66 adjudicated causes of 
death. Most participants (809) were given co-trimoxazole prior to entry. Forty-seven events, 
including 7 TB-related deaths, were confirmed as HIV/AIDS-related, 8 were non-HIV-
related, 1 was due to renal failure in the IPT arm attributed to tenofovir); there was 
insufficient information for another 10 deaths. In addition to increased age, pre-ART risk 
factors independently associated with early mortality included slightly lower CD4 count, 
lymphadenopathy, lower hemoglobin, decreased albumin, higher WBC, and higher 
neutrophil percent (Table 1; Figure 1a–e). WHO stage 3 or 4 conditions at baseline were not 
associated with early mortality (Table 1).
Seven-hundred and forty-six of 850 (88%) participants, including 43 who died, had 
complete baseline and week-4 data available for the complete case analysis of early response 
and survival (Supplemental Figure 1). Nine participants who died and 1 who was lost to 
follow-up before week 4 were excluded from week-4 analyses. Participants initially 
excluded from the week-4 assessment appeared slightly sicker in terms of lower hemoglobin 
and BMI and somewhat greater prevalence of WHO grade 3 or 4 conditions than those 
included (Supplemental Table 2). Table 3 presents early virologic and immunologic 
responses stratified by post-week 4 mortality on ART for both the complete case and 
multiple imputation analyses, which included 840 participants (850 randomized minus 10 
who died or were lost prior to week 4) and 58 deaths. In complete case analysis, the median 
4-week changes in CD4 count and viral load for deaths vs non-deaths after week 4 were 26 
vs 56 cells/mm3 and −2.7 vs −2.7 log10 copies/mL, respectively (Table 3). While the median 
change in viral load was the same among those who died and those who survived, the 
distributions were different, as evidenced by the 3rd quartile of change in viral load being 
smaller in those who died compared to those who survived (−0.4 vs. −2.4 log10 copies/mL). 
Lower virologic responses may have been related to lower early adherence, since the median 
number of weeks participants were completely adherent to their prescribed HIV medications 
over the first 3 weeks were 2.8 weeks among those who survived (n=758) and 2.5 weeks 
among those who died (n=48; p=0.02). Sub-optimal early CD4 count change and early 
virologic responses were independently associated with early mortality after adjusting for 
age, sex, BMI, hemoglobin, baseline CD4, baseline viral load, and newly diagnosed WHO 
stage 3 or 4 conditions (Table 3).
Results for complete case and multiple imputation analyses were consistent with respect to 
early immune recovery associations (Table 3). In the multiple imputation analysis, each 20 
unit lower change in week 4 CD4 count was associated with a 20% increased risk of death 
(adj. HR 1.20, 1.01–1.42; Figure 2). Overall, 43 of 746 (5.7%) were newly diagnosed with 
an OI at week 4 (Table 3). Specific newly diagnosed OIs are listed in Supplemental Table 3. 
Newly diagnosed WHO stage 3 or 4 conditions were associated with an increased risk of 
post-week-4 mortality in the complete-case analysis but the hazard ratio crossed 1 in the 
multiple imputation analysis (adj. HR 2.03, 0.87–4.72).
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Twenty-four participants alive at week 4 were missing week 4 CD4 and viral load data due 
to a missed visit. Of these 24 participants, 11 (46%) died prior to week 48. In a separate 
analysis using multiple imputation but excluding these 24 participants, the association of 
mortality with CD4 and viral load change remained the same (Supplemental Table 4). 
Sensitivity analyses where imputed CD4 change and viral load change were shifted by fixed 
amounts in this group of participants produced similar results under a variety of scenarios 
(Supplemental Table 5).
Discussion
In this study, 7.9% of HIV-infected adults initiating ART with CD4 counts <50 cells/mm3 
died during 48 weeks of follow-up. Pre-ART factors associated with death were 
lymphadenopathy, lower hemoglobin, lower albumin, slightly lower CD4 count, higher 
WBC count and higher neutrophil percent. Lower CD4 increases in the initial 4 weeks of 
therapy were also independently associated with an increased risk of subsequent mortality 
despite virologic suppression. Taken together, these data suggest that early detection and 
treatment of OIs prior to ART initiation and rapid early immune recovery are key to survival 
on ART in advanced HIV disease.
Evaluating risk factors for mortality on ART in a group of individuals with advanced HIV 
disease revealed several findings that differ from previous studies. For example, a lower pre-
ART CD4 count is consistently a strong risk factor for early mortality in a population where 
a broad range of baseline CD4 counts are represented (3). In this study, however, baseline 
CD4 counts were significantly lower in those who died, but the absolute difference was 
small and not clinically useful. Similarly, several studies have documented an association 
between BMI and survival on ART (15, 16). However, in this population albumin levels, a 
marker of macronutrient status, and not BMI itself (measured as a continuous or 
dichotomous variable), were associated with death. This may suggest a role for nutritional 
interventions in HIV-infected patients presenting for HIV care, as recommended by WHO 
(17). However, decreased hepatic albumin synthetic function may also relate to the presence 
of active infections, which appeared to play a prominent role in treatment outcomes in this 
population. Of note, higher pre-ART WBC counts and neutrophil percentages, both risk 
factors for death in this study, were plausibly due to co-infections that were present but 
undiagnosed at baseline. Consistent with this, leukocytosis was an independent risk factor 
for mortality in a South African cohort with a median CD4 count of 106 cells/mm3 (18), and 
neutrophilia has previously been associated with TB-associated mortality in hospitalized 
patients in South Africa (19). Notably, in the present study many of these deaths were not 
attributed to TB. These data indicate that diagnostic and treatment strategies capable of 
addressing a diverse array of coinfections in populations with advanced HIV are needed at 
the time of ART initiation and soon thereafter.
The magnitude of immunologic response after several months of ART is associated with 
longer-term survival in HIV-infected individuals (20, 21), but less is known about the 
relationship between early CD4 recovery and early mortality. One study among HIV-
infected adults with pulmonary TB in Botswana (median pre-ART CD4 count of 61 
cells/mm3) examined the association between the week-4 CD4 count change and death 
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within 24 weeks after ART initiation (6). As in the present report, patients who died had a 
clinically meaningful and significantly lower change in the CD4 cell count from baseline to 
week 4 (median difference of 49 cells/mm3) compared to survivors (6). Our study findings 
confirm this association in a diverse patient population with highly advanced HIV disease 
without known TB at the time of ART initiation. Notably, in both studies the median 
virologic responses at week 4 after ART were similar among those who subsequently died or 
survived, although some of those who died (i.e., those in the lowest virologic response 
quartile) had minimal virologic response (6). These data suggest that virologic suppression, 
while a necessary first step in ART response, does not necessarily ensure clinical recovery in 
advanced HIV. Substantial early CD4 reconstitution appears crucial. The data also suggest 
that in patients with advanced HIV infection integrase inhibitor-based ART, which has been 
associated with more rapid virologic and immunologic responses (22, 23), may prove 
beneficial. Further controlled study in cohorts with advanced HIV is needed.
Our study has several limitations. Early CD4 count recovery is largely due to redistribution 
of T cells from lymphatic tissue (24), and data on factors that might impact immune 
recovery, such as the extent of lymph node fibrosis and immune activation prior to ART 
initiation (25, 26), were unavailable. Multiple studies have evaluated factors associated with 
longer-term immune recovery on ART (26–28), whereas few have focused on determinants 
of early immune restoration. Nonetheless, our data is consistent with findings from Uganda, 
where incident TB after ART initiation was associated with sub-optimal immune recovery 
during ART (29). Second, while the large patient population was diverse with respect to 
region, patients were followed in clinical trial settings and had a relatively low mortality 
rate. Thus, the results may not be generalizable to sites where close follow-up is not 
performed or to sites that do not screen for TB or administer IPT. Because most deaths were 
AIDS related, however, the relationship between CD4 recovery and mortality would likely 
be stronger in settings where the incidence of OIs was higher. Third, some participants died 
prior to week 4, limiting our ability to analyze CD4 changes in these individuals. Exclusion 
of these participants, who may have very poor immune recovery, could have resulted in our 
underestimating the strength of the association between early CD4 recovery and death. 
Finally, the prognostic and therapeutic value of CD4 counts are unclear in an era where ART 
is recommended for all HIV-infected individuals. Yet, our data suggest that patients with 
sub-optimal levels of immune recovery may plausibly benefit from more intensive 
evaluation and diagnostics. The predictive utility of this approach needs evaluation.
WHO now recommends ART for all HIV-infected individuals regardless of CD4 count (30), 
and optimal lab testing and evaluation prior to ART initiation are debated (31). In the present 
study, despite close observation in a trial and despite use of anti-tubercular drugs, 
approximately 1 in 14 starting ART with advanced HIV did not survive the first year of 
therapy. The associations between mortality, slow immune response and newly diagnosed 
OIs underscores the need for careful clinical evaluation of patients with very advanced HIV 
prior to and soon after ART initiation. Further research evaluating how this can be 
accomplished in an era of decentralization and differentiated HIV care is needed.
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Refer to Web version on PubMed Central for supplementary material.
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Figures 1. 
a–e: Survival curves for baseline laboratory risk factors for early mortality after ART 
initiation identified by multivariable analysis. Pre-ART values of 1.a) CD4 count (above or 
below 25 cells/mm3, 1.b) albumin (dichotomized at 30 gm/L), 1.c) white blood cell count 
(dichotomized at median), and 1.d) neutrophil percentage (dichotomized at median) and 1.e) 
hemoglobin (dichotomized at 8 gm/dL) are shown.
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Figure 2. 
Survival curves for post-week 4 mortality and week 4 CD4 cell count change above or below 
20 cells/mm3 from baseline.
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Table 2
Primary Causes of Early Mortality in in Adults Initiating Antiretroviral Therapy with Advanced HIV Disease
Treatment Strategy
Empiric
(N=30)
IPT
(N=36)
Total
(N=66)
Primary Cause of Death HIV infection or HIV-related diagnosis 23 (77%) 24 (67%) 47 (71%)
    Pulmonary or extra pulmonary tuberculosis 3 4 7
    Pulmonary – respiratory disease/failure 4 3 6
    Bacterial Sepsis 1 3 4
    Cryptococcal meningitis 2 2 4
    Hematologic disease (other than clotting) 2 2 4
    Cardiovascular shock 2 1 3
    Kaposi Sarcoma 3 0 3
    Bacterial pneumonia – probable 1 1 2
    Pneumocystis carinii pneumonia 1 0 1
    Other 4 8 12
  Non-HIV diagnosis 2 (7%) 6 (17%) 8 (12%)
  Toxicity 0 (0%) 1 (3%) 1 (2%)
  No information available 5 (17%) 5 (14%) 10 (15%)
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